RT Journal Article
SR Electronic
T1 Late-breaking abstract: Role of interferon-á2b and ribavirin in MERS-CoV infection as treatment and prophylaxis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2453
VO 44
IS Suppl 58
A1 Mohammed Khalid
A1 Basha Khan
A1 Khaliq Agha Rehan
A1 Quaid Nadri
A1 Abdullah Al Mobeireek
A1 Ruwaida AlIsmaili
A1 Mehar Rehman
A1 Taimur Butt
A1 Mohammed Zeitouni
A1 Abdullah Al Dalaan
A1 Sarfraz Saleemi
A1 Khalid Maghrabi
A1 Eid Al Mutairy
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2453.abstract
AB Introduction: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Kingdom with 60% mortality is alarming. We report 6 patients with MERS-CoV infection treated with Interferon-á2b and Ribavirin. Results:All MERS-CoV positive PCR. Active disease 1-4 (Table 1), 2 asymptomatic contacts 5-6 (table 1) out of 53contacts tested for virus. Active patient progressed to respiratory and multisystem failure. Patient 1-3 (table 1) were older age/comorbid condition, died. Patient #4 (Table 1) was diagnosed early with treatment recovered. 2 contact cases with early lung infiltrates which resolved after treatment.Discussion:MERS-CoV is associated with high mortality. It attaches to DPP4 receptors in the lower respiratory tract, kidneys, liver and prostate leading to respiratory and multi-organ failure. Older patients with comorbid condition and delay in treatment associated in high mortality. Treatment in proven and asymptomatic contacts may prevent mortality and morbidity.Conclusion: MERS-CoV infection is associated with high mortality in older patients with comorbid condition and in whom diagnosis and the treatment is delayed. Early intervention for confirmed cases with disease manifestation and confirmed MERS CoV asymptomatic cases may respond to the treatment. Human to human transmission is quite low.View this table:Table1:Patients Overview